Drug development is hampered by a lack of information on several different biological, physiological, and social factors relevant to the human body, drug related properties and the study trial design.
Modelling and Simulation (M&S strategy) has been widely developed these recent years in the pharmaceutical sector under the standards, protocols and resources required to evaluate the safety and the efficacy of medical devices and/or medicines through all the drug development process. Biosimulation not only helps in predicting the chances of drug failure, but also lowers the cost of the development process by reducing the number of clinical trials.
PhysPK, developed by Empresarios Agrupados, is one of the most innovative bio simulation software in the market, that combines PBPK, PK, PD and Systems Biology – Pharmacology methodologies under a customizable software, designed for current industry needs and ready to evolve with emerging challenges.
Moderator: Ignacio Vieira
Dr. Eduardo Rodenas
VP Scientific Officer. Life Sciences Strategy & Intelligence B.U. Head Azierta
Dr. Antonio Borregón
VP Global Business Development Azierta
Audit & Certification, Healthcare, Digital Science & Growth, Health & Infrastructures Director Azierta
Director of Simulation Area Empresarios Agrupados
Modeling and Simulation Pharmacokinetics Technician Empresarios Agrupados
1.Welcome and Opening Speakers: Dr. Antonio Borregón & Miguel Alcázar
2.Drug development: framework and current challenges Speaker: Dr. Eduardo Ródenas
3.Biosimulation: main goals and new opportunities Speaker: Ignacio Vieira
4.PhysPK: Simulation Software for Physiological Systems Speakers: Miguel Alcázar & Sergio Sánchez
Join to the webinar
Please fill the form below to complete the registration for the webinar